Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way - 25 Breakout Stars in Ongoing television Series
- 3The 10 Most Noteworthy Games in History
- 4Dominating the Art of Composing: Creator Bits of knowledge
- 5Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Famous Kitchen Finishing Styles For 2024
- Manual for Individual accounting Rudiments for Fledglings
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- Farmers worry about rising cost of fertiliser
- Why some African countries are prone to military takeovers
- Map shows more than 1,900 measles cases across U.S.
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- Public Parks in the USA
